AU;Current Trials
  • Home
  • Clinical Trials
  • Chronic Cough Study Kapiti P3

Chronic Cough Study

Kapiti

Please note that this study has now closed. However, we encourage you to pre-register your interest for upcoming Chronic Cough studies here.

Description

What to expect

Study details

Ages

18 to 80 years old

Duration

Approximately 64 weeks with 21 scheduled clinic visits and 2 phone visits

Compensation

Participants will be compensated for reasonable expenses associated with study visits

Eligibility Criteria

You may qualify if you:

  • Are 18 to 80 years old
  • Have had a chronic cough for 12 months or more
  • Have not responded to treatments for underlying causes OR
  • Have an unexplained cough despite testing
  • Are a non-smoker or have been smoke-free for at least 6 months

Other eligibility criteria apply. A study team member will determine if this study is right for you.

Locations

Kapiti

Description

Refractory or Unexplained Chronic Cough is a persistent cough that lasts longer than eight weeks and can occur when no clear cause is found. It affects millions of people worldwide and often continues despite treatment for conditions such as asthma, reflux or infections. 

People living with chronic cough may experience frequent coughing fits that disrupt sleep, speech, and daily life, sometimes leading to anxiety and social withdrawal. Although chronic cough isn’t life threatening, it can severely affect physical comfort and emotional well-being. 

Current treatment for chronic cough focus on managing potential underlying causes, but they often do not relieve symptoms and the cough remains persist. That’s why new approaches are urgently needed.

In recent years, research has shifted toward targeting the nerve pathways that trigger coughing. This study is investigating a medication that works by blocking the nerve receptors thought to trigger coughing. The goal is to reduce cough frequency and severity by calming the overactive cough reflux. 

By joining this study, you’ll contribute to research exploring whether the investigational medicine can offer meaningful relief for individuals living with chronic cough.

What to expect

Participants in this study will be randomly assigned to receive the investigational medication or a placebo.

During the initial 24-week phase, you’ll take the randomly assigned medication twice daily and attend regular clinic visits for health assessments and cough monitoring. 

If you complete this phase, you may enter the 28-week open-label extension, where all participants will receive the investigational medication. 

As part of the study, you will also be asked to wear a 24-hour ambulatory cough recorder. This small, wearable device tracks how often you cough throughout the day and night, allowing researchers to understand how the treatment is working.

 

Why join a clinical research study?

- Gain early access to new potential treatments at no cost

- Contribute to research that could improve the lives of others living with Chronic Cough

- Learn to better manage your condition

- Receive health checks and advice from our professional medical team

 

Your privacy is important. All personal information will be kept strictly confidential.

Register your interest today.

This study is now closed

Please note that this study has now closed. However, we encourage you to pre-register your interest for upcoming Chronic Cough studies here.

More Chronic Cough Studies
Therapeutic AreasClinical TrialsAboutContactCareersNews
ParticipantsSponsors

New Zealand locations

WellingtonTaurangaHawke's BayKapitiPalmerston NorthLower HuttDunedinPukekohe AucklandPCRN Clinical Trial Sites

Australian locations

Fortitude Valley BrisbaneTaringa BrisbaneWellers Hill BrisbaneSunshine MelbourneDarlinghurst SydneySt Leonards Sydney

2025 © Momentum Clinical Research

Privacy Policy